Effect of HIV constructs containing protease-reverse transcriptase fusion proteins on viral replication

AIDS

Volumn 12, Issue 9, 1998, Pages 967-975

  Cherry, Elana ^a   Morin, Nicolas ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Frameshift site mutation; Fusion protein; Protease; Reverse transcriptase; Trans dominant effect

Indexed keywords

HYBRID PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ANIMAL CELL; ARTICLE; CELL STRAIN; FRAMESHIFT MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0032543542     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199809000-00003     Document Type: Article

References (31)

1. Gottlinger HG, Sodroski JG, Haseltine WA: Role of capsid precursor processing and myristylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1989, 86:5781-5785.
2. Katoh I, Ikawa Y, Yoshinaka Y: Retrovirus protease characterized as a dimeric aspartic protease. J Virol 1989, 63:2226-2232.
3. Kohl NE, Emini EA, Schleif WA, et al.: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988, 85:4686-4690.
4. Peng C, Ho BK, Chang TW, Chang NT: Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989, 63:2550-2556.
5. Kaplan AH, Zack JA, Knigge M, et al.: Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 1993, 67:4050-4055.
6. Arrigo SJ, Huffman K: Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. J Virol 1995, 69:5988-5994.
7. Karacostas V, Wolffe EJ, Nagashima K, Gonda MA, Moss B: Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virol 1993, 193:661-671.
8. Mergener K, Facke M, Welker R, Brinkmann V, Geklerblom HR, Krausslich H-G: Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells. Virology 1992, 186:25-39.
9. Mildner AM, Rothrock DJ, Leone JW, et al.: The HIV-1 protease as enzyme and substrate: mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties. Biochemistry 1994, 33:9405-9413.
10. Babe LM, Pichuantes S, Craik CS: Inhibition of HIV protease activity by heterodimer formation. Biochemistry 1991, 30:106-111.
11. Babe LM, Rose J, Craik CS: Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci USA 1995, 92:10069-10073.
12. Bahner I, Zhou C, Yu X-J, Hao Q-L, Guatelli JC, Kohn DB: Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993, 67:3199-3207.
13. Bevec D, Dobrovnik M, Hauber J, Bohnlein E: Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci USA 1992, 89:9870-9874.
14. Buchschacher GLJ, Freed EO, Panganiban AT: Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant. J Virol 1995, 69:1344-1348.
15. Junker U, Escaich S, Plavic I, et al.: Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines. J Virol 1996, 70:7765-7772.
16. Malim MH, Feimuth WW, Lie J, et al.: Stable expression of transdominant Rev proteins in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992, 176:1197-1201.
17. Smythe JA, Sun D, Thomson M, et al.: A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1994, 91:3657-3661.
18. Trono D, Feinberg MB, Baltimore D: HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989, 59:113-120.
19. El-Farrash MA, Kuroda MJ, Kitazaki T, et al.: Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol 1994, 68:233-239.
20. Ho DD, Toyoshima T, Mo H, et al.: Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 1994, 68:2016-2020.
21. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
22. Zhang ZY, Poorman RA, Maggiora LL, Heinrikson RL, Kezdy FJ: Dissociative inhibition of dimeric enzymes, kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J Biol Chem 1991, 266:15591-15594.
23. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison III CA: Complete mutagenesis of the HIV-1 protease. Nature 1989, 340:397-400.
24. Pettit SC, Simsic J, Loeb DD, Everitt L, Hutchison III CA, Swanstrom R: Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem 1991, 266:14539-14547.
25. Poorman RA, Tomasselli AG, Heinrikson RL, Kezdy FJ: A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J Biol Chem 1991, 266:14554-14561.
26. Park J, Morrow CD: Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol 1991, 65:5111-5117.
27. Boulerice F, Bour S, Geleziunas R, Lvovich A, Wainberg MA: High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol 1990, 64:1745-1755.
28. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory; 1982.
29. Quan Y, Cu Z, Li X, Morrow C, Wainberg MA: Endogenous reverse transcriptase assays reveal high-level resistance to the triphosphate of (-)2′-dideoxy-3′-thiacytidine by mutated M184V human immunodeficiency virus type 1. J Virol 1996, 70:5642-5645.
30. Hughes BP, Booth TF, Belyaev AS, McIlroy D, Jowett J, Roy P: Morphogenic capabilities of human immunodeficiency virus type 1 gag and gag-pol proteins in insect cells. Virology 1993, 193:242-255.
31. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA: Effect of mutations affecting the p6 Gag protein on human immunodeficiency virus particle release. Proc Nat Acad Sci USA 1991, 88:3195-3199.